<DOC>
	<DOCNO>NCT02690701</DOCNO>
	<brief_summary>This study evaluate effect secukinumab compare placebo aortic vascular inflammation adult patient moderate severe plaque psoriasis poorly control current psoriasis treatment .</brief_summary>
	<brief_title>Study Evaluate Effect Secukinumab Compared Placebo Aortic Vascular Inflammation Subjects With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males female least 18 year age moderate severe plaque psoriasis Forms psoriasis chronic plaque psoriasis Previous exposure IL17A IL17 receptor target agent . Other active ongoing disease may interfere evaluation psoriasis place patient unacceptable risk Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>secukinumab</keyword>
	<keyword>AIN457</keyword>
	<keyword>biologic</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>